GlassScriptPhysician profile
Jose A Torres
NPI 1083619282
$10,458.46
in general payments reported to CMS, 2019-2025
35 companies · $1,435 in 2025
The $1,435 reported for 2025 was more than what 78% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,144 · 2020: $867 · 2021: $1,563 · 2022: $1,504 · 2023: $1,769 · 2024: $2,176 · 2025: $1,435.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,280 · Education: $99.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,280.22 |
| Education | $99.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $2,674.90 | 2019-2025 | Opsumit, Uptravi, Opsynvi |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $992.37 | 2019-2025 | Lifevest |
| United Therapeutics Corporation | $858.71 | 2019-2024 | Tyvaso, Orenitram, Remodulin |
| Amgen INC. | $737.53 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $582.60 | 2020-2025 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $525.51 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $521.56 | 2022-2025 | Verquvo, Winrevair |
| Novartis Pharmaceuticals Corporation | $450.67 | 2019-2025 | |
| Pfizer INC. | $438.88 | 2019-2024 | |
| Edwards Lifesciences Corporation | $333.25 | 2019-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Sapien 3 Ultra Resilia |
| Janssen Pharmaceuticals, INC | $275.30 | 2019-2024 | Xarelto |
| Esperion Therapeutics, INC. | $249.58 | 2020-2025 | Nexletol |
| Boston Scientific Corporation | $217.88 | 2024-2025 | Watchman Flx, Watchman Access System, Cds - Mct/Cem Monitoring |
| Novo Nordisk INC | $190.92 | 2019-2025 | Wegovy |
| E.R. Squibb & Sons, L.L.C. | $166.14 | 2021-2025 | Camzyos |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.97 | 2020-2022 | |
| Abiomed | $136.57 | 2024-2025 | Impella |
| Baxter Healthcare | $134.58 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Alnylam Pharmaceuticals INC. | $130.44 | 2024-2025 | Amvuttra |
| Abbott Laboratories | $114.90 | 2021-2024 | Mitraclip |
| Arbor Pharmaceuticals, INC. | $108.94 | 2019-2021 | |
| Azurity Pharmaceuticals, INC. | $87.89 | 2023-2025 | Edarbyclor, Edarbi, Horizant |
| Astellas Pharma US INC | $79.99 | 2020 | |
| Sanofi-Aventis U.S. LLC | $51.53 | 2019-2022 | |
| Lexicon Pharmaceuticals, INC. | $38.92 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $32.38 | 2019-2021 | |
| Vital Connect, INC | $25.06 | 2024 | Vitalpatch Rtm |
| Regeneron Healthcare Solutions, INC. | $23.58 | 2022 | |
| Medicure Pharma INC. | $21.63 | 2021 | |
| Medicomp INC | $20.75 | 2023 | Telepatch Cardiac Monitor |
| Kestra Medical Technology Services, INC. | $17.06 | 2022 | |
| Phadia US INC. | $16.71 | 2022 | |
| Biosense Webster, INC. | $16.29 | 2019 | |
| Glaxosmithkline, LLC. | $14.47 | 2025 | Arexvy, Shingrix |
| Bardy Diagnostics, INC. | $13.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Torres listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.